Patients With Cutaneous Graft Versus Host Disease News Today : Breaking News, Live Updates & Top Stories | Vimarsana

A cream formulation of ruxolitinib was deemed safe and effective compared with placebo in patients with cutaneous graft-versus-host disease.

Galina markovaCellular therapy meetingsInpatient consultative dermatologyDermatology serviceMemorial sloan kettering cancer centerGlobal assessmentClinical conditionComposite assessmentIndex lesion disease severityDermtech smartCream formulation of ruxolitinibPatients with cutaneous graft versus host disease